Forest Conley, DO
Family Medicine · Moberly, MONPI 1982603452
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 393 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,790 and has fallen 95.8% since, to $76 in 2025. Among family medicine clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 393 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$955
- AbbVie$760
- AstraZeneca$726
- Pfizer$560
- Boehringer Ingelheim$295
- Novartis$294
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,313100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 60 | $955 |
| AbbVie(2 entities) | 48 | $760 |
| AstraZeneca | 46 | $726 |
| Pfizer | 36 | $560 |
| Boehringer Ingelheim | 18 | $295 |
| Novartis | 17 | $294 |
| GSK | 20 | $281 |
| Johnson & Johnson | 15 | $281 |
| Novo Nordisk | 19 | $265 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $256 |
| Bayer | 11 | $199 |
| Merck | 13 | $188 |
| Sunovion Pharmaceuticals Inc. | 10 | $115 |
| Amgen | 6 | $113 |
| Sanofi-aventis U.S. LLC | 8 | $111 |
| E.r. Squibb & Sons, L.L.C. | 5 | $103 |
| Otsuka America Pharmaceutical, Inc. | 5 | $103 |
| Abbott | 5 | $82 |
| Radius Health, Inc. | 5 | $77 |
| Teva Pharmaceuticals USA, Inc. | 4 | $70 |
| Amarin Pharma, Inc. | 4 | $64 |
| Kowa Pharmaceuticals America, Inc. | 2 | $52 |
| Grifols USA, LLC | 3 | $48 |
| Eisai Inc. | 3 | $42 |
| Genentech USA, Inc. | 2 | $41 |
| Mylan Specialty L.p. | 2 | $39 |
| Nevro Corp. | 2 | $39 |
| Exact Sciences | 2 | $38 |
| Astellas Pharma US Inc | 1 | $23 |
| Viatris Specialty LLC | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Globus Medical | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
How this compares
$6,314 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $37,598 |
| TrulicityDulaglutide | 15 | $24,168 |
| FarxigaDapagliflozin Propanediol | 20 | $23,324 |
| JardianceEmpagliflozin | 24 | $22,975 |
| OzempicSemaglutide | 17 | $19,753 |
| VraylarCariprazine Hcl | 12 | $16,711 |
| Liothyronine Sodium | 187 | $14,420 |
| JanuviaSitagliptin Phosphate | 12 | $13,601 |
| XareltoRivaroxaban | 32 | $11,086 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $6,744 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,246 |
| Celecoxib | 54 | $2,623 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $2,557 |
| Aripiprazole | 17 | $2,120 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 97 | $1,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $281 | $37,59847 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat | $295 | $35,96548 claims |
| Lilly USA, LLCTrulicity | $955 | $24,16815 claims |
| AstraZenecaFarxiga | $726 | $23,32420 claims |
| Novo NordiskOzempic | $265 | $19,75317 claims |
| AbbVieVraylar, Armour Thyroid | $760 | $18,52349 claims |
| MerckJanuvia | $188 | $13,60112 claims |
| Johnson & JohnsonXarelto | $281 | $11,08632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Moberly
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- Roger CadySpringfield$175K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
- Blair ThedingerKansas City$71K
- Christine MooreRaymore$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.